Fri, July 22, 2022
Thu, July 21, 2022
Wed, July 20, 2022

Ami Fadia Maintained (BIIB) at Strong Buy with Decreased Target to $250 on, Jul 21st, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. th-decreased-target-to-250-on-jul-21st-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Ami Fadia of Needham, Maintained "Biogen Inc." (BIIB) at Strong Buy with Decreased Target from $262 to $250 on, Jul 21st, 2022.

Ami has made no other calls on BIIB in the last 4 months.



There are 6 other peers that have a rating on BIIB. Out of the 6 peers that are also analyzing BIIB, 1 agrees with Ami's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Geoff Meacham of "B of A Securities" Maintained at Hold with Decreased Target to $225 on, Monday, March 28th, 2022


These are the ratings of the 5 analyists that currently disagree with Ami


  • Jay Olson of "Oppenheimer" Maintained at Buy with Increased Target to $230 on, Monday, July 18th, 2022
  • Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $251 on, Wednesday, May 4th, 2022
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $285 on, Wednesday, May 4th, 2022
  • Marc Goodman of "SVB Leerink" Maintained at Buy with Decreased Target to $270 on, Thursday, April 21st, 2022
  • Mohit Bansal of "Wells Fargo" Upgraded from Hold to Buy and Increased Target to $265 on, Monday, April 18th, 2022

Publication Contributing Sources